Overview

A Trial Investigating the Within-subject Variability of NN1250 in Subjects With Type 1 Diabetes

Status:
Completed
Trial end date:
2009-10-26
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this clinical trial is to evaluate the variability in the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc